Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2022-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a390e35cfea740088dde947cfb51ea7b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Sun Joo Cha |e author |
| 700 | 1 | 0 | |a Kiyoung Kim |e author |
| 245 | 0 | 0 | |a Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection |
| 260 | |b MDPI AG, |c 2022-01-01T00:00:00Z. | ||
| 500 | |a 10.3390/antiox11020195 | ||
| 500 | |a 2076-3921 | ||
| 520 | |a Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to treat amyotrophic lateral sclerosis. The distinguishing pathogenic features of neurodegenerative diseases include high reactive oxygen species levels and mitochondrial dysfunction. However, the correlation between mitochondria and edaravone has not been elucidated. This review highlights recent studies on novel therapeutic perspectives of edaravone in terms of its effect on oxidative stress and mitochondrial function. | ||
| 546 | |a EN | ||
| 690 | |a edaravone | ||
| 690 | |a oxidative stress | ||
| 690 | |a antioxidant | ||
| 690 | |a mitochondria | ||
| 690 | |a neurodegenerative disease | ||
| 690 | |a amyotrophic lateral sclerosis | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Antioxidants, Vol 11, Iss 2, p 195 (2022) | |
| 787 | 0 | |n https://www.mdpi.com/2076-3921/11/2/195 | |
| 787 | 0 | |n https://doaj.org/toc/2076-3921 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a390e35cfea740088dde947cfb51ea7b |z Connect to this object online. |